We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,193

“Reverse payment” settlements face greater antitrust scrutiny following U.S. Supreme Court ruling in FTC v. Actavis
  • McDermott Will & Emery
  • USA
  • July 31 2013

Resolving a split among the U.S. Courts of Appeals, the U.S. Supreme Court ruled that patent infringement settlement agreements between branded and


Feds’ argument in favor of premium tax credit gains momentum, still under attack in federal courts
  • McDermott Will & Emery
  • USA
  • February 26 2014

A second federal district court judge has ruled in favor of the government on one of the most serious challenges to the Patient Protection and


Generic drug and API producers deal with the Bolar exemption
  • McDermott Will & Emery
  • Germany
  • February 26 2014

To allow generic drug companies to enter the market as seamlessly as possible after expiration of patent rights, the Bolar exemption allows certain


French Sunshine Act finally implemented
  • McDermott Will & Emery
  • France
  • May 22 2013

The decree implementing French Law No. 2011-2012 on the Strengthening of Health Protection for Medicinal and Health Products (the decree), known as


Florida medical record disclosure law preempted by HIPAA
  • McDermott Will & Emery
  • USA
  • May 20 2013

The U.S. Court of Appeals for the 11th Circuit recently ruled that a Florida law requiring nursing homes to disclose patient records of deceased


The new EU clinical trials regulation aims at harmonization and transparency
  • McDermott Will & Emery
  • European Union
  • October 20 2014

On June 16, 2014, Reg. (EU) No. 5362014 on Clinical Trials on Medicinal Products for Human Use (Regulation) has entered into force. Once it becomes


Old compound known purpose prior art concentrations obvious
  • McDermott Will & Emery
  • USA
  • December 31 2013

In a split panel decision, the U.S. Court of Appeals for the Federal Circuit reversed a district court concluding that the claims at issue were


Finalized ACA regulations on transitional reinsurance program premiums and potential effects for employer-sponsored group health plans
  • McDermott Will & Emery
  • USA
  • March 6 2013

As part of the Patient Protection and Affordable Care Act, the U.S. Department of Health and Human Services (HHS) recently released final regulations


New HIPAA regulations require action by group health plans
  • McDermott Will & Emery
  • USA
  • March 7 2013

Final HIPAA privacy and security regulations issued by the U.S. Department of Health and Human services will require action by group health plan


CMS delays edits to deny claims when orderingreferring provider not enrolled in Medicare and issues proposed rule on enrollment restrictions
  • McDermott Will & Emery
  • USA
  • May 13 2013

The Centers for Medicare & Medicaid Services temporarily delayed the implementation of edits relating to orderingreferring practitioners that were